Skip to content

This site is intended for healthcare professionals in the UK only. Prescribing information and Adverse Event (AE) reporting details can be found in the footer.

  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs
  • Why Zegluxen®
    • Therapeutic indications
    • Clinical efficacy
    • Mechanism of action
    • Patient eligibility
  • Cost savings
  • How to Administer
    • Dose Titration
    • Storage and shelf life
    • Method of administration
  • Safety & Tolerability
    • Possible side effects
    • Special warnings and precautions for use
    • Special populations
    • Drug interactions
  • Supporting information
    • FAQs

Storage and shelf life

Instructions on how to store Zegluxen® 

Two Zegluxen packs side-by-side

Instructions on how to store Zegluxen® 

How to Store

Before opening Zegluxen® should be stored in the refrigerator (2˚C–8˚C) but not frozen and placed away from the freezer compartment. The shelf-life of Zegluxen® is 24 months, but after first use, should be either stored below 30˚C or refrigerated and used within 30 days.

For full details of storage, please see section 6.3 and 6.4 of the SmPC.1

UV protection of pen

Patients should be advised to keep the pen cap on in order to protect the medication from light.

For full details of storage and use of pen, please see section 6.3 and 6.4 of the SmPC.1

Bearded and tattooed man leaning back on chair

1. Zegluxen® (liraglutide) Summary of Product Characteristics.

000697560 | December 2024

Prescribing information can be found here

  • Navigation
    • Terms of Use
    • HCP Privacy
    • Cookies Policy
    • GDPR

MORE ABOUT US

linkedin

Reporting of side effects

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Zentiva Pharma UK Ltd via our online form (https://www.zentiva.co.uk/contact/mi-form), by email (UKMedInfo@zentiva.com) or by telephone (0800 090 2408).

Copyright Zentiva Group, a.s. © 2025

I confirm I am a UK Healthcare Professional (HCP)

This page is dedicated to UK HCPs only. If you are not a UK HCP, you will be directed to the gateway page after clicking on No.

No, I am not Yes, I am